Alspaugh Jonathan 4
4 · Aeglea BioTherapeutics, Inc. · Filed Aug 18, 2021
Insider Transaction Report
Form 4
Alspaugh Jonathan
Chief Financial Officer
Transactions
- Purchase
Common Stock
2021-08-17$6.50/sh+23,392$151,985→ 33,172 total - Purchase
Common Stock
2021-08-16$6.37/sh+9,780$62,275→ 9,780 total - Purchase
Common Stock
2021-08-18$6.72/sh+7,200$48,400→ 40,372 total
Footnotes (3)
- [F1]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.13 to $6.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
- [F2]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.6 per share, inclusive.
- [F3]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.69 to $6.77 per share, inclusive.